Navigation Links
Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
Date:10/24/2007

this study had enrolled 26 patients with a variety of advanced solid tumors. 11 of 21 patients assessable for tumor response receiving doses of XL647 ranging from 75 to 300 mg achieved stable disease for at least three months. The XL647 exposure with daily dosing at the maximum tolerated dose (MTD) (300 mg) in this study was approximately twofold higher over a 28-day cycle compared to the exposure observed previously at the MTD (350 mg) for the intermittent dosing regimen. XL647 was generally well tolerated and related Grade 3 adverse events were infrequent. No Grade 3 or greater skin rash was reported in this study. Pharmacodynamic analyses were conducted in plasma samples and eyebrow hair follicles. Biomarker changes consistent with EGFR inhibition were observed in eyebrow hair follicles following XL647 treatment.

"The phase 2 data continue to show encouraging anti-tumor activity for XL647 given on an intermittent schedule in previously untreated clinically selected NSCLC patients. Additionally, phase 1 data suggest that XL647 dosed daily at 300 mg is well tolerated and provides approximately twofold higher drug exposure over a 28-day cycle compared to intermittent dosing," said George A. Scangos, Ph.D., president and chief executive officer of Exelixis. "We are pleased to continue to see evidence of good tolerability and no Grade 3 rash with XL647, and believe that a daily dosing strategy may have the potential to further enhance the anti-tumor activity in NSCLC."

The most common treatment-related adverse events (AEs) were Grade 1 and 2 diarrhea and dysgeusia, fatigue, rash, and clinically asymptomatic QTc prolongation. In phase 1, a total of ten serious AEs were reported in six patients; of these events, two were considered possibly or probably related to XL647. These two drug-related events of Grade 3 pneumonitis and Grade 4 myocardial infarction occurred in the same patient. The cohort was expanded, and no further dose-limiting toxicities (DLTs) w
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Telbec/ - Russell Williams , President of ... the 2015-2016 Quebec Budget, noting the fiscal discipline and ... industry. However, the association is concerned about the decline ... government,s intent to strive for a balanced budget this ... Quebec,s economic development is encouraging," said ...
(Date:3/27/2015)... VICTORIA, Texas , March 27, 2015  Victoria Vein ... removal services with the Astanza Duality laser in ... of vein disease as well as advanced laser treatments for ... are entering the tattoo industry to provide more services for ... Surgery has helped many Victoria residents ...
(Date:3/27/2015)... March 27, 2015 A new report from Kalorama ... – Chile , ... top targets for IVD firms.  The healthcare research firm said ... IVD strategies for the Latin American continent with a population ... distributed supply operations. However, the country,s regional economic clout does ...
Breaking Medicine Technology:Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3Victoria Vein And Surgery Clinic Uses Advanced Astanza Duality Tattoo Removal Technology 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4
(Date:3/28/2015)... 28, 2015 Coffee could not only perk ... you from gum disease, researchers have found. , They found ... , Coffee contains antioxidants. Antioxidants fight gum disease. Does coffee, ... at Boston Univ. Henry M. Goldman School of Dental Medicine ... 2014 issue of the Journal of Periodontology. , “This is ...
(Date:3/28/2015)... 2015 With more than 4,500 ... of osteoporosis, osteoarthritis and musculoskeletal diseases gathered here ... be the first time in the 17-year history ... the hot-button topic is an emerging non-pharmaceutical protocol ... scientific principles of Wolff’s law, osteogenic loading at ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 India ... coverage is made available to all visitors who purchase ... immediately. All members are encouraged to purchase the insurance ... avoid lack of proper coverage for pre-existing medical conditions. ... one or two medical conditions with serious consequences to ...
(Date:3/28/2015)... One in three young athletes who ... today at the American Orthopaedic Society for Sports Medicine’s ... long term success of surgery for patients aged 18 ... from 242 patients who underwent ACL reconstruction between 1993 ... FRACS, from North Sydney Orthopaedic and Sports Medicine Centre. ...
(Date:3/28/2015)... 28, 2015 Genomic medicine experts have ... revealing, for the first time, key information for understanding ... read the newly posted story on the Surviving ... of British Columbia, the British Columbia Cancer Agency, and ... reveal underlying molecular alterations and mutations that can lead ...
Breaking Medicine News(10 mins):Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2
... <A HREF=",http://chinese.eurekalert.org/zh/emb_releases/2010-01/yu-stt011110.php,">Chinese . Stress induces ... Yale researchers have discovered. The research, published ... , describes a novel way cancer takes hold ... attack the deadly disease. Until now, most researchers ...
... too little shut-eye, study finds , WEDNESDAY, Jan. 13 (HealthDay ... has on functioning and thinking cannot be reversed by one ... of good sleep can make you feel and operate better ... loss linger much longer. , In fact, "chronic sleep loss ...
... , NEW YORK , ... Eric Spiegel has been named president and CEO of ... expert, starts the position on January 18 . ... Senior Vice President and Senior Partner at Booz & Co. ...
... in the general population use the drug responsibly, study finds ... taking Viagra will lead to sexually risky behavior can relax: ... make men more likely to engage in potentially unhealthy sex. ... a doctor who may worry that prescribing erectile-dysfunction drugs to ...
... climbing, government study finds , WEDNESDAY, Jan. 13 (HealthDay News) ... in the United States may finally be stabilizing instead of ... obesity remain high, with about one-third of Americans still falling ... heavy 6- to 19-year-old boys appear to be increasing. , ...
... around dental implants is far more common than previously realised, ... of Gothenburg, Sweden. Around a quarter of patients loose some ... X-rays of over 600 patients. The more implants a patient ... find loss of supporting bone. Just over a quarter - ...
Cached Medicine News:Health News:Stress triggers tumor formation, Yale researchers find 2Health News:A Good Night's Slumber Won't Reverse Chronic Sleep Loss 2Health News:A Good Night's Slumber Won't Reverse Chronic Sleep Loss 3Health News:Siemens Taps Top Energy Expert as New Head of U.S. Business 2Health News:Siemens Taps Top Energy Expert as New Head of U.S. Business 3Health News:Taking Viagra Won't Spur Risky Sexual Behavior 2Health News: U.S. Obesity Rates Leveling Off, But Still High 2Health News: U.S. Obesity Rates Leveling Off, But Still High 3
Designed to address the specific demands of the busy operating environment, the AL1 Light Source features state-of-the art 180W Xenon lamp technology, providing light output suitable for all endoscop...
LCD monitors....
Standard arthroscope with telescope (4 mm) for large joints....
... Endoscopy Components, LLC offers ... Equipment "Made in Germany". ... manufactured according to ISO ... most excellent design elements ...
Medicine Products: